BioWorld MedTech

Feb. 29, 2016

Elite French investors pump fresh $55 million into artificial heart

PARIS — To fund its ramp-up to market, artificial heart maker Paris-based Carmat SA raised €50 million ($55 million) through a reserved capital increase put together by a cluster of elite French institutional investors. Read More

Spectranetics hopeful for a stellar year, fueled by Stellarex DCB

OA trials numerous but endpoints tricky as stakeholders search for another way

International Stroke Conference tPA costs and their impact on AIS therapies addressed at meeting

Panel says a heavy hand will impede use of NGS in oncology

Other News to Note

Appointments & Advancements

Keeping you up to date on recent developments in Neurology

Today's news in brief

BioWorld

BioWorld briefs for June 17, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...

Gene replacement rescues autism-related phenotypes in mice

BioWorld Science

Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...